top of page
The Professional Network for Healthcare Experts
FDA approves Roche Tecentriq combination as first adjuvant immunotherapy for stage III dMMR colon cancer
The FDA has approved Roche's Tecentriq-based chemotherapy regimen as the first adjuvant immunotherapy option for eligible patients with stage III mismatch repair-deficient colon cancer.
nuaxia
28 minutes ago2 min read
FDA Approves Roche’s Tecentriq in First ctDNA-Guided Cancer Therapy
Landmark decision ties bladder cancer treatment to molecular residual disease testing
nuaxia
May 182 min read
bottom of page